Form 144 | DaVita(DVA.US) Officer Proposes to Sell 693.84K in Common Stocks
SEC FILLINGS DISCLOSED/ May 10, $DaVita(DVA.US)$ Officer DESOER BARBARA J intends to sell 5,030 shares of its common stock on May 10, with a total market value of approximately $693.84K. Source: An
Are You Looking for a Top Momentum Pick? Why DaVita HealthCare (DVA) Is a Great Choice
DaVita Honors 54 Nephrology Nurses With DAISY Awards
Award celebrates excellence in nursing, underscoring the kidney care provider's commitment to recognizing the indelible impact of clinicians on outstanding patient care DENVER, May 9, 2024 /PRNewswire
DaVita Inc. to Participate in the BofA Securities 2024 Health Care Conference
DENVER, May 9, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will parti
4 Stocks to Buy in a Thriving Outpatient Home Health Industry
The Zacks Analyst Blog Highlights DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant
Calculating The Intrinsic Value Of DaVita Inc. (NYSE:DVA)
Key Insights The projected fair value for DaVita is US$119 based on 2 Stage Free Cash Flow to Equity DaVita's US$137 share price indicates it is trading at similar levels as its fair value estimate
TD Cowen Adjusts Price Target on DaVita to $139 From $136
DaVita (DVA) has an average hold rating and a price target range of $122 to $169, according to analysts polled by Capital IQ. Price: 136.00, Change: -0.87, Percent Change: -0.64
DaVita Is Maintained at Equal-Weight by Barclays
DaVita Is Maintained at Equal-Weight by Barclays
Barclays Maintains Equal-Weight on DaVita, Raises Price Target to $150
Barclays analyst Andrew Mok maintains DaVita with a Equal-Weight and raises the price target from $133 to $150.
DaVita Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 10.63% Barclays $133 → $150 Maintains Equal-Weight 03/06/2024 -1.91% Barclays → $133 Initiates
Goldman's Top 50 Weak Balance Sheet Stocks
Goldman Sachs analysts listed 50 stocks constituents of their “weak balance sheet” basket.
DaVita Inc. Just Beat EPS By 28%: Here's What Analysts Think Will Happen Next
US stocks closed | NASDAQ rose about 2%, Apple surged 6% after the results, and Nvidia rose more than 3%
The three major US stock indexes closed up at least 1%; Amgen led the S&P and Dow, the diet drug duo Lilai once fell more than 3%, and Novo Nord Europe shares once fell more than 5%; the chip stock index closed up more than 2% and still fell throughout the week. Qualcomm's sharp rise fell back the next day, and AMD earnings fell more than 4% in the week
Research Alert: CFRA Reiterates Hold View On Shares Of Davita Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month price target to $1
DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up
AEON Biopharma, Allarity Therapeutics, ModivCare Among Healthcare Movers
Earnings Call Summary | DaVita(DVA.US) Q1 2024 Earnings Conference
The following is a summary of the DaVita Inc. (DVA) Q1 2024 Earnings Call Transcript:Financial Performance:DaVita reported Q1 2024 adjusted operating income of $463 million and adjusted earnings per s
Barclays Adjusts Price Target on DaVita to $150 From $133
DaVita (DVA) has an average hold rating and a price target range of $122 to $145, according to analysts polled by Capital IQ. Price: 149.65, Change: +7.41, Percent Change: +5.21
Truist Financial Keeps Their Hold Rating on DaVita (DVA)
No Data